Seed Innovations Ltd / AIM: SEED / Sector: Closed End Investments

29 August 2024

SEED Innovations Limited

("SEED" or the "Company")

Notice of Annual General Meeting and Investor Presentation

SEED Innovations Ltd, the AIM-quoted investment company offering exposure to disruptive, high-growth, life sciences and technology ventures typically inaccessible to everyday investors, is pleased to announce that its Annual General Meeting ("AGM") will be held at 2 p.m. (BST) on the 24 September 2024 at Suite 8, 16-20 Upper House, Smith Street, St Peter Port, Guernsey and virtually via Investor Meet Company (see instructions to enable participation below). 

A copy of the Company's Annual Report & Audited Financial Statements (the "Annual Report"), Notice of AGM, and accompanying Form of Proxy have been published and are available to view and download on the Company's website: https://seedinnovations.co/.

In order to allow shareholders to follow the proceedings of the AGM without attending in person, the Company will provide access online via the Investor Meet Company platform. Please note that investors will  not be able to vote online and are requested to submit their votes via proxy as early as possible.

Shareholders are invited to submit any questions for the Board to consider. Questions can be pre submitted ahead of the AGM via the Investor Meet Company Platform up until 9 a.m. (BST) on the 23 September 2024 or submitted at any time during the AGM itself.

Immediately following the formal AGM meeting and as part of the same call, the Board will provide a short investor update.

Shareholders that wish to attend the AGM remotely should register for the event in advance by using the following link: https://www.investormeetcompany.com/seed-innovations-limited/register-investor. Investors who already follow SEED Innovations Ltd, on the Investor Meet Company  platform will automatically be invited.

- Ends -

For further information visit: www.seedinnovations.co or contact:

Notes

Seed Innovations Ltd is an AIM quoted investment company offering exposure to disruptive, high-growth, life sciences and technology ventures typically inaccessible to everyday investors. Its strategy focuses on identifying early-stage opportunities with upcoming investment catalysts, alongside more mature investments providing near-term liquidity. With a portfolio of such investments and cash reserves, the company is agile and poised to capitalise swiftly on new investment opportunities.